SI-Bone Shares Up After Receiving FDA Approval for Expanded Device Use
Provided by
Dow Jones
By Rob Curran
Shares of SI-Bone rose after the medical-device maker received clearance from the Food and Drug Administration to market its bone-implant device for more indications and applications.
Shares ticked up to $20.60 in premarket trading.
The Santa Clara, Calif, firm said it received 510(K) premarket clearance for its iFuse Bedrock Granite implant in a smaller diameter, with an indication for pediatric patients and expanded application.
SI-Bone's technology is used to treat muscular-skeletal disorders, as part of spinal fusion treatments.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
January 30, 2024 09:10 ET (14:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year